Simvastatin for lowering lipids

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2023-02-24

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1002/14651858.cd014857
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis.

  2022cited by this paper
• Cerivastatin for lowering lipids.

  2020cited by this paper
• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

  2019cited by this paper
• Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis.

  2019cited by this paper
• 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cited by this paper
• Fluvastatin for lowering lipids.

  2018cited by this paper
• Lipid-lowering efficacy of rosuvastatin.

  2017cited by this paper
• Pitavastatin for lowering lipids.

  2017cited by this paper
• Lipid-lowering efficacy of atorvastatin.

  2015cited by this paper
• Statins for the primary prevention of cardiovascular disease

  2014cited by this paper
• Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

  2012cited by this paper
• Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

  2011cited by this paper
• Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial

  2011cited by this paper
• Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors--United States, 2011.

  2011cited by this paper
• The impact of social determinants on cardiovascular disease.

  2010cited by this paper
• A systematic review and meta‐analysis on the therapeutic equivalence of statins

  2010cited by this paper
• Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

  2009cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• The LDL receptor.

  2009cited by this paper
• Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin

  2008cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• A systematic review and economic evaluation of statins for the prevention of coronary events.

  2007cited by this paper
• Imputing missing standard deviations in meta-analyses can provide accurate results.

  2006cited by this paper
• Pleiotropic effects of statins.

  2005cited by this paper
• Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.

  2004cited by this paper
• Simvastatin: a review

  2004cited by this paper
• Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

  2003cited by this paper
• Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials

  2003cited by this paper
• Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

  2003cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

  1999cited by this paper
• The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe.

  1997cited by this paper
• FOCUS ON ATORVASTATIN : AN HMG-COA REDUCTASE INHIBITOR FOR LOWERING BOTH ELEVATED LDL CHOLESTEROL AND TRIGLYCERIDES IN HYPERCHOLESTEROLEMIC PATIENTS

  1997cited by this paper
• Dose-Response Characteristics of Cholesterol-Lowering Drug Therapies: Implications for Treatment

  1996cited by this paper
• Manual of Pharmacologic Calculations

  1987cited by this paper

• Unraveling novel pancreatic lipase and cholesterol esterase inhibitory peptides in Oryza Sativa L. and their mechanism by peptidomics, molecular dynamics simulations, and cell study

  2026cites this paper
• Ethyl Acetate Fraction of Gynura procumbens Mitigates Hyperglycemia, Dyslipidemia, and Tissue Damage in Streptozotocin-Induced Diabetic Rats

  2025influential citation
• Effects of Baccharis dracunculifolia DC on an Innovative Animal Model of Cardiometabolic Syndrome

  2024cites this paper
• Lovastatin for lowering lipids

  2023cites this paper